ANTENGENE-B (06996.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow - Longbridge

Quote List Quote List

Event Tracking

Oct27

Anteon Biotech Displays ATG-201 Preclinical Data and Plans to Advance to Clinical Development

01:00

Sep16

ATHEX repurchased 29,500 shares for HKD 197,700

11:44

Sep10

Ataichan Biopharma repurchased 146,000 shares

10:51

Sep3

Atreca Receives Breakthrough Therapy Designation and Plans to Repurchase Shares

05:40

Sep1

Deer MediTech Plans to Repurchase up to 40 Million HKD in Shares

04:28

Aug27

Dat Biopharma's ATG022 Receives Breakthrough Therapy Designation in China and Unveils Latest Data

01:21

Schedules & Filings

Schedules

Filings

Aug22

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Revenue 29.1 M, Net Income -41.8 M, EPS -0.0673

Mar21

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Revenue 16.58 M, Net Income -80.97 M, EPS -0.1301

Aug23

Earning Release(CST)

FY2024 Q2 Earning Release (HKD) Revenue 32.65 M, Net Income -89.74 M, EPS -0.1449

View More

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change

View More